These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 8427853)

  • 1. Impact of weight loss on plasminogen activator inhibitor (PAI-1), factor VII, and other hemostatic factors in moderately overweight adults.
    Folsom AR; Qamhieh HT; Wing RR; Jeffery RW; Stinson VL; Kuller LH; Wu KK
    Arterioscler Thromb; 1993 Feb; 13(2):162-9. PubMed ID: 8427853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemostatic variables, carbohydrate metabolism and lipid profile in women with low body mass index.
    Polac I; Stachowiak G; Jedrzejczyk S; Stetkiewics T; Sobieszczanska S; Pertynski T
    Gynecol Endocrinol; 2003 Apr; 17(2):151-7. PubMed ID: 12744226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibrinogen, coagulation factor VII, tissue plasminogen activator, plasminogen activator inhibitor-1, and lipid as cardiovascular risk factors in chronic hemodialysis and continuous ambulatory peritoneal dialysis patients.
    Tomura S; Nakamura Y; Doi M; Ando R; Ida T; Chida Y; Ootsuka S; Shinoda T; Yanagi H; Tsuchiya S; Marumo F
    Am J Kidney Dis; 1996 Jun; 27(6):848-54. PubMed ID: 8651250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between obesity and a prothrombotic state: the Framingham Offspring Study.
    Rosito GA; D'Agostino RB; Massaro J; Lipinska I; Mittleman MA; Sutherland P; Wilson PW; Levy D; Muller JE; Tofler GH
    Thromb Haemost; 2004 Apr; 91(4):683-9. PubMed ID: 15045128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma levels of tissue plasminogen activator and plasminogen activator inhibitor-1 are correlated with the presence of transplant coronary artery disease in cardiac transplant recipients.
    Warshofsky MK; Wasserman HS; Wang W; Teng P; Sciacca R; Apfelbaum M; Schwartz A; Michler RE; Mancini DM; Cannon PJ; Rabbani LE
    Am J Cardiol; 1997 Jul; 80(2):145-9. PubMed ID: 9230149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alcohol consumption and hemostatic factors: analysis of the Framingham Offspring cohort.
    Mukamal KJ; Jadhav PP; D'Agostino RB; Massaro JM; Mittleman MA; Lipinska I; Sutherland PA; Matheney T; Levy D; Wilson PW; Ellison RC; Silbershatz H; Muller JE; Tofler GH
    Circulation; 2001 Sep; 104(12):1367-73. PubMed ID: 11560851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Visceral fat accumulation and its relation to plasma hemostatic factors in healthy men.
    Cigolini M; Targher G; Bergamo Andreis IA; Tonoli M; Agostino G; De Sandre G
    Arterioscler Thromb Vasc Biol; 1996 Mar; 16(3):368-74. PubMed ID: 8630661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transdermal estrogen replacement therapy: beneficial effects on hemostatic risk factors for cardiovascular disease.
    Lindoff C; Peterson F; Lecander I; Martinsson G; Astedt B
    Maturitas; 1996 May; 24(1-2):43-50. PubMed ID: 8794433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased plasminogen activator inhibitor-1 activity in offspring of type 2 diabetic patients: lack of association with plasma insulin levels.
    Gürlek A; Bayraktar M; Kirazli S
    Diabetes Care; 2000 Jan; 23(1):88-92. PubMed ID: 10857975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term treatment with growth hormone decreases plasminogen activator inhibitor-1 and tissue plasminogen activator in growth hormone-deficient adults.
    Johansson JO; Landin K; Johannsson G; Tengborn L; Bengtsson BA
    Thromb Haemost; 1996 Sep; 76(3):422-8. PubMed ID: 8883281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relationship between cardiometabolic and hemostatic variables: influence of race.
    Perry A; Wang X; Goldberg R; Ross R; Jackson L
    Metabolism; 2008 Feb; 57(2):200-6. PubMed ID: 18191049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasminogen activator inhibitor-1, tissue-type plasminogen activator, and fibrinogen: Effect of dieting with or without exercise in overweight postmenopausal women.
    Svendsen OL; Hassager C; Christiansen C; Nielsen JD; Winther K
    Arterioscler Thromb Vasc Biol; 1996 Mar; 16(3):381-5. PubMed ID: 8630663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postmenopausal oral estrogen therapy affects hemostatic factors, but does not account for reduction in the progression of subclinical atherosclerosis.
    Vigen C; Hodis HN; Chandler WL; Lobo RA; Mack WJ
    J Thromb Haemost; 2007 Jun; 5(6):1201-8. PubMed ID: 17389005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of saturated fat and n-6 polyunsaturated fat on postprandial lipemia and hemostatic activity.
    Salomaa V; Rasi V; Pekkanen J; Jauhiainen M; Vahtera E; Pietinen P; Korhonen H; Kuulasmaa K; Ehnholm C
    Atherosclerosis; 1993 Oct; 103(1):1-11. PubMed ID: 8280180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction in factor VII, fibrinogen and plasminogen activator inhibitor-1 activity after surgical treatment of morbid obesity.
    Primrose JN; Davies JA; Prentice CR; Hughes R; Johnston D
    Thromb Haemost; 1992 Oct; 68(4):396-9. PubMed ID: 1448769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in haemostatic variables induced by oral contraceptives containing 50 micrograms or 30 micrograms oestrogen: absence of dose-dependent effect on PAI-1 activity.
    Scarabin PY; Plu-Bureau G; Zitoun D; Bara L; Guize L; Samama MM
    Thromb Haemost; 1995 Sep; 74(3):928-32. PubMed ID: 8571323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hemostasis profile and lipid metabolism with long-interval use of a desogestrel-containing oral contraceptive.
    Cachrimanidou AC; Hellberg D; Nilsson S; von Schoulz B; Crona N; Siegbahn A
    Contraception; 1994 Aug; 50(2):153-65. PubMed ID: 7956214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of moderate weight loss on anginal symptoms and indices of coagulation and fibrinolysis in overweight patients with angina pectoris.
    Hankey CR; Lean ME; Lowe GD; Rumley A; Woodward M
    Eur J Clin Nutr; 2002 Oct; 56(10):1039-45. PubMed ID: 12373626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of oestrogen dose and progestogen type on haemostatic changes in women taking low dose oral contraceptives.
    Norris LA; Bonnar J
    Br J Obstet Gynaecol; 1996 Mar; 103(3):261-7. PubMed ID: 8630312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with a GnRH analogue: effects on hemostatic risk factors for thrombo-embolic disease.
    Lindoff C; Petersson F; Samsioe G; Astedt B
    Int J Fertil Menopausal Stud; 1994; 39(3):133-9. PubMed ID: 7920748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.